AANMS Theranostics Course Presentations 2024
Brisbane 24 – 25 August 2024
1. Official Welcome – Prof Jennifer Martin (RACP President), Uncle Billy Cummings (Turrbal People representative)
2. AANMS Theranostics Update – Prof Sze Ting Lee
3. How to establish a patient-centred theranostics service – AProf Grace Kong
4. Medical physics for the theranostics specialist – Dr Kathy Willowson
5. Radiochemistry for the theranostics specialist – Dr Mohammad Haskali
6. Palliative Care Principles for theranostics – Dr Katrina Kramer
7. Introduction to theranostics Q&A Panel Discussion
8. NETs overview & functional syndromes – Dr Cherie Chiang
9. NETs surgical treatment principles – AProf Benjamin Loveday
10. Oncologic treatment of NETs update – Dr David Chan
11. Molecular imaging of NETs update – AProf Grace Kong
12. NETs Radionuclide Therapy MDT session – Lead Grace Kong Panel Gabby Cehic, William MacDonald, David Chan, Cherie Chiang, Aa
13. NET Imaging MDT session – Leads Nattakorn Dhiantravan & Samuel Kyle Panel Grace Kong, Gabby Cehic, David Chan, Cherie Chian
14. Peptide Receptor Radionuclide Therapy update – AProf Gabby Cehic
15. The NET patient consultation – AProf Grace Kong
16. Radiobiology & theranostics – Dr William Macdonald
17. NETs Therapy Q&A Panel Discussion
18. Prostate cancer overview & early treatment options – Dr Matthew Roberts
19. Metastatic prostate cancer therapy update – Dr Jeffrey Goh
20. Prostate cancer a patient perspective – Supported by Movember
21. PSMA PET diagnosis & staging – Prof Michael Hofman
22. PSMA PET in the setting of biochemical recurrence – AProf Roslyn Francis
23. PSMA PET response assessment criteria – Prof Louise Emmett
24. Prostate Cancer Imaging MDT session – Leads Evyn Arnfield & Roslyn Francis Panel Oliver Sartor, Michael Hofman, Louise Emme
25. Prostate cancer clinical trials and imaging Q&A Panel Discussion
26. Insights from the VISION & PSMAfore trials – Prof Oliver Sartor
27. LuPSMA key trials update – Dr Sarennya Pathmanandavel
28. Appropriate LuPSMA clinical indications & treatment protocols in 2024 – Prof Michael Hofman
29. Patient selection criteria for LuPSMA in 2024 – Dr Nattakorn Dhiantravan
30. PSMA Radioligand Therapy MDT session – Leads Louise Emmett & Sobia Khan Panel Oliver Sartor, Michael Hofman, Matthew Robert
31. Clinical overview & treatment landscape – AProf Donald McLeod
32. Molecular imaging & RAI therapy overview – Prof Sze Ting Lee
33. Re-differentiation therapy & the I-FIRST trial – AProf David Pattison
34. Advanced thyroid cancer MDT session – Lead James McNeil Panel David Pattison, Elizabeth Thomas, Monica Rossleigh, Donald Mc
35. Thyroid cancer Q&A Panel Discussion
36. Future of theranostics alpha & combination therapies – Prof Michael Hofman
37. Paediatric theranostics neuroblastoma & thyroid cancer update – Dr Elizabeth Thomas
38. Selective Internal Radiation Therapy – Dr Samuel Davis
39. Peptide Receptor Radionuclide Therapy for meningioma- Dr Geoff Schembri
40. Rh-188 for Non Melanoma Skin Cancer – Dr Joe Cardaci
41. Other Theranostic therapies Q&A Panel Discussion
42. Lutetium therapy practicalities lessons from the coalface David Macfarlane, Mohammad Haskali, Stephanie Lindores, Matthew Gr
43. Artificial Intelligence & Theranostics Dr Aaron Wong
44. Role of ARTNET in Theranostics trials AProf Roslyn Francis
45. Global perspective on theranostics Prof Andrew Scott
46. Beyond the Clinic Q&A Panel Discussion
47. Concluding remarks AProf David Pattison